This week on Careers in Discovery, we welcome back Dave Hallett, now Chief Scientific Officer at Recursion, following the recent merger with Exscientia.

The last five years have been transformative for Dave, from leading AI-driven drug discovery at Exscientia to navigating one of Biotech’s biggest IPOs and stepping into the CEO role in a challenging market. Now, he’s focused on proving that AI-designed medicines can deliver real impact, with clinical results beginning to emerge.

We discuss the evolution of AI in drug discovery, the lessons Dave has learned leading a publicly listed company, and why the industry must focus on reducing drug development failure rates to make new medicines more accessible.

A fascinating conversation with a leader at the forefront of Biotech innovation.